<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Farnesyltransferase inhibitors (FTIs) target proteins needing prenylation for functioning </plain></SENT>
<SENT sid="1" pm="."><plain>Tipifarnib (Zarnestra), a potent and specific inhibitor of farnesyltransferase, showed considerable activity in phase I and II studies in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), but the optimal regimen achieving high response rates with minor <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> remains to be determined </plain></SENT>
<SENT sid="2" pm="."><plain>Additionally, a direct effect on purified human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors has not yet been shown </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells isolated by using immunomagnetic beads were plated for short-term cultures in semisolid media or liquid cultures for flow-cytometric assessment of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the presence of either DMSO or various FTI concentrations </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Tipifarnib exerted selective in vitro toxicity against clonal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> hematopoiesis at concentrations less than 10 nM the effect being more prominent in white cell progenitors </plain></SENT>
<SENT sid="5" pm="."><plain>This action was not due to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction as both <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors displayed equivalent DiOC3 and annexin V expression up to 72 h after exposure to tipifarnib </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The leukemic clone is more susceptible in tipifarnib than <z:mpath ids='MPATH_458'>normal</z:mpath> progenitors </plain></SENT>
<SENT sid="7" pm="."><plain>Since <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> represents the main obstacle in the clinical use of tipifarnib in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, further reduction of the currently employed dose will potentially result in a more tolerable regimen without compromising its antileukemic action </plain></SENT>
</text></document>